LivaNova PLC: LivaNova Reports Second Quarter 2021 Results and Appoints Alex Shvartsburg as Chief Financial Officer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
LivaNova PLC: LivaNova Reports First Quarter 2021 Results
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2021.
For the first quarter of 2021, worldwide sales from continuing operations were $247.6 million, an increase of 2.1 percent on a reported basis and a decline of 0.4 percent on a constant-currency
1 basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), first quarter 2021 diluted loss per share from continuing operations was $0.61. First quarter 2021 adjusted diluted earnings per share from continuing operations was $0.35. Epilepsy sales growth in the quarter reflects improving market dynamics, especially in the United States. The pace of vaccination efforts, along with patients and their caregivers willingness to seek treatment, is key to the continued recovery of the Epilepsy business, said Damie
LivaNova PLC: LivaNova Reports Fourth Quarter and Full-Year 2020 Results
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2020.
For the fourth quarter of 2020, worldwide sales from continuing operations were $269.6 million, a decrease of 6.3 percent on a reported basis and a decline of 7.7 percent on a constant-currency
1 basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), fourth quarter 2020 diluted loss per share from continuing operations was $5.74. Fourth quarter 2020 adjusted diluted earnings per share from continuing operations was $0.71.